Sector News

Fury at EU Commission pharma policy move

September 15, 2014
Life sciences
The new European Commission says it will remove responsibility for medicines, including the European Medicines Agency, from the Directorate-General for Health and Consumers and give it back to DG Enterprise and Industry, in a development which has appalled health activists.
This “opaque and unjustified” decision by President-elect Jean-Claude Juncker’s new Commission “will put the commercial, profit-driven interests of the pharmaceutical industry, rather than patients and consumers, at the heart of European policymaking on medicines,” warns Health Action International (HAI). Pharmaceuticals are integral to enhancing public health, so they belong within the portfolio of DG Health and Consumers (DG SANCO), which is mandated to protect health and well-being, it says.
Jim Murray, a former director of the European Consumer Organisation (BEUC), has described the move as “a good day for the pharmaceutical industry, but a bad day for public health.”
No Directorate-General should combine the lead role for medicines policy with the lead role for the promotion of the pharmaceutical industry, says Mr Murray, writing on the EurActiv blogging platform BlogActiv. The difficult tasks of balancing the interests of public health and the legitimate interests of the pharmaceutical industry should not take place within the one DG, and should not be well-hidden from public scrutiny, he says, and also points to the difficulty of ensuring the right mix of skills within a single unit or DG, combining specialists in public health with expertise in industrial promotion.
The European Public Health Alliance (EPHA) has also condemned the move as “a potential disaster.” The group points out that among the reasons for moving health technology and pharmaceutical policy to DG SANCO in 2009 was to facilitate emergency preparedness in response to the emergence of H1N1 and the alleged inability of DG Enterprise to provide the necessary leadership and coordination of vaccines, and to harmonise pharmaceutical governance along the lines of the EU member states, all of which manage pharmaceutical policy under their health ministries.
“It is disappointing that President-elect Juncker believes these objectives fall a pale second place to appeasing big business,” said EPHA president Peggy Maguire. “The [EU] College of Commissioners should work for the interest of citizens and not anonymous corporate masters,” she added.
According to HAI, the transferral of the EMA to DG Enterprise and Industry is particularly troubling, and will create significant threats to clinical trial data transparency in the European Union (EU). “EMA had encountered significant opposition to its policy on public access to clinical trial data from the pharmaceutical industry in the last year. Now, the strong opposition from the industry will be more loudly heard by the EMA, and will most likely jeopardise independent review and, ultimately, patient safety,” the group warns.
By Lynne Taylor
Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]